

Appendix 1. Search Strategy

Medline

#	Search term	Results
1	exp Testicular Neoplasms/	25770
2	(testic* cancer or testis cancer*).tw.	6266
3	(testic* tumor or testis tumo?r*).tw.	2170
4	(testic* carcinoma or testis carcinoma*).tw.	578
5	(testic* malignan* or testis malignan*).tw.	408
6	testicular germ cell tumo?r*.tw.	2560
7	urological cancer*.tw.	816
8	genitourinary cancer*.tw.	633
9	testicular cancer.mp.	5913
10	seminoma*.tw.	7171
11	non seminoma*.tw.	1749
12	sertoli cell*.tw.	11442
13	leydig cell.tw.	5665
14	or/1-13	45269
15	Quality of Life/	189212
16	patient reported outcome measures/	5109
17	(patient adj1 rated).tw.	1975
18	patient-reported outcome*.tw.	16271
19	(patient adj1 reported).tw.	31769
20	quality of life.tw.	267991
21	self-rated.tw.	13158
22	self-report*.tw.	150544
23	QL.tw.	1491
24	QOL.tw.	36841
25	HRQL.tw.	3398
26	HRQOL.tw.	15703
27	PROM.tw.	2658
28	PRO.tw.	187611
29	health status/	79884
30	health status.tw.	56168

31	or/15-30	764087
32	trial.tw.	581995
33	randomi*.tw.	623188
34	32 or 33	911335
35	14 and 31	791

Database: CINAHL

Search ID	Search Terms	Actions
S26	S13 AND S25	(236)
S25	S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24	(337,323)
S24	TI health status OR AB health status OR MH health status	(81,763)
S23	TI PROM OR AB PROM OR MH PROM	(1,639)
S22	TI PRO OR AB PRO OR MH PRO	(24,974)
S21	TI HRQOL OR AB HRQOL OR MH HRQOL	(7,732)
S20	TI HRQL OR AB HRQL OR MH HRQL	(1,468)
S19	TI qol OR AB qol OR MH qol	(16,038)
S18	TI QL OR AB QL OR MH QL	(364)
S17	TI self-report* OR AB self-report* OR MH self-report*	(84,658)
S16	TI self-rated OR AB self-rated OR MH self-rated	(8,124)
S15	TI patient reported outcome measures OR AB patient reported outcome measures OR MH patient reported outcome measures	(3,244)
S14	TI "Quality of life" OR AB "Quality of life" OR MH "Quality of life"	(169,863)
S13	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12	(4,703)
S12	TI leydig cells OR AB leydig cells OR MH leydig cells	(333)
S11	TI sertoli cell OR AB sertoli cell OR MH sertoli cell	(340)
S10	TI non seminoma OR AB non seminoma OR MH non seminoma	(68)
S9	TI seminoma OR AB seminoma OR MH seminoma	(599)
S8	TI genitourinary cancer OR AB genitourinary cancer OR MH genitourinary cancer	(303)

S7	TI urological cancer OR AB urological cancer OR MH urological cancer	(233)
S6	TI testicular germ cell tumour OR AB testicular germ cell tumour OR MH testicular germ cell tumour	(270)
S5	TI testicular malignancy OR AB testicular malignancy OR MH testicular malignancy	(94)
S4	TI testicular carcinoma OR AB testicular carcinoma OR MH testicular carcinoma	(82)
S3	TI testicular tumour OR AB testicular tumour OR MH testicular tumour	(611)
S2	TI testicular neoplasms OR AB testicular neoplasms OR MH testicular neoplasms	(3,129)
S1	TI testicular cancer OR AB testicular cancer OR MH testicular cancer	(1,439)

Embase

1	exp Testicular Neoplasms/	31881
2	testis cancer/	13116
3	"quality of life"/	457768
4	patient-reported outcome/	20862
5	1 or 2	31881
6	3 or 4	472126
7	5 and 6	625
8	remove duplicates from 7	620

PubMed

((quality of life[MeSH Terms]) OR (patient reported outcome[MeSH Terms])) AND ((testis cancer[MeSH Terms] OR (testicular neoplasms[MeSH Terms])))

Appendix 2: List of included studies.

1. Arai Y, Kawakita M, Hida S, Terachi T, Okada Y, Yoshida O. Psychosocial aspects in long-term survivors of testicular cancer. *J Urol*. 1996;155(2):574-8.
2. Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. *Journal of the National Cancer Institute*. 2009;101(24):1682-95.
3. Bumbasirevic U, Bojanic N, Pekmezovic T, Janjic A, Janicic A, Milojevic B, et al. Health-related quality of life, depression, and sexual function in testicular cancer survivors in a developing country: a Serbian experience. *Support Care Cancer*. 2013;21(3):757-63.
4. Caffo O, Amichetti M, Tomio L, Galligioni E. Quality of life after radiotherapy for early-stage testicular seminoma. *Radiother Oncol*. 2001;59(1):13-20.
5. Dearnaley DP, Fossa SD, Kaye SB, Cullen MH, Harland SJ, Sokal MP, et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). *Br J Cancer*. 2005;92(12):2107-13.
6. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. *J Clin Oncol*. 2001;19(6):1629-40.
7. Flechtner HH, Fischer F, Albers P, Hartmann M, Siener R. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. *Eur Urol*. 2016;69(3):518-25.
8. Fossa SD, Aass N, Kaalhus O. Testicular cancer in young Norwegians. *J Surg Oncol*. 1988;39(1):43-63.
9. Fossa SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). *J Clin Oncol*. 2003;21(6):1107-18.
10. Fossa SD, Moynihan C, Serbouti S. Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study. *Support Care Cancer*. 1996;4(2):118-28.
11. Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, et al. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. *J Clin Oncol*. 2017;35(11):1211-22.
12. Gamulin M, Grgic M, Bisof V. Side effects of adjuvant radiotherapy in men with testicular seminoma stage I. *Arh Hig Rada Toksikol*. 2011;62(3):235-41.

13. Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. *Cancer*. 2010;116(10):2322-31.
14. Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebiski VJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. *Journal of the National Cancer Institute*. 2010;102(16):1253-62.
15. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C. Long-term effects on sexual function and fertility after treatment of testicular cancer. *Br J Cancer*. 1999;80(5-6):801-7.
16. Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. *Br J Cancer*. 2005;93(2):200-7.
17. Joly F, Heron JF, Kalusinski L, Bottet P, Brune D, Allouache N, et al. Quality of life in long-term survivors of testicular cancer: a population-based case-control study. *J Clin Oncol*. 2002;20(1):73-80.
18. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). *J Clin Oncol*. 2005;23(6):1200–1208. doi:10.1200/JCO.2005.08.003
19. Jonker-Pool G, van Basten JP, Hoekstra HJ, van Driel MF, Sleijfer DT, Koops HS, et al. Sexual functioning after treatment for testicular cancer: comparison of treatment modalities. *Cancer*. 1997;80(3):454-64.
20. Kaasa S, Aass N, Mastekaasa A, Lund E, Fossa SD. Psychosocial well-being in testicular cancer patients. *Eur J Cancer*. 1991;27(9):1091-5.
21. Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, et al. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: A multi-institutional study. *J Clin Oncol*. 2018;36(15):1505-12.
22. Kim C, McGlynn KA, McCorkle R, Erickson RL, Niebuhr DW, Ma S, et al. Quality of life among testicular cancer survivors: a case-control study in the United States. *Qual Life Res*. 2011;20(10):1629-37.
23. Miyake H, Muramaki M, Eto H, Kamidono S, Hara I. Health-related quality of life after chemotherapy for advanced germ cell tumors: a comparison of standard-dose and high-dose chemotherapy. *Int J Urol*. 2004;11(7):542-6.
24. Mykletun A, Dahl AA, Haaland CF, Bremnes R, Dahl O, Klepp O, et al. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. *J Clin Oncol*. 2005;23(13):3061-8.
25. Oechsle K, Hartmann M, Mehnert A, Oing C, Bokemeyer C, Vehling S. Symptom burden in long-term germ cell tumor survivors. *Support Care Cancer*. 2016;24(5):2243-50.
26. Oldenburg J, Fossa SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. *Qual Life Res*. 2006;15(5):791-800.

27. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. *J. 2007*;5:70.
28. Oliver RT, Edmonds PM, Ong JY, Ostrowski MJ, Jackson AW, Baille-Johnson H, et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? *Int J Radiat Oncol Biol Phys. 1994*;29(1):3-8.
29. Poulakis V, Skriapas K, de Vries R, Dillenburg W, Ferakis N, Witzsch U, et al. Quality of life after laparoscopic and open retroperitoneal lymph node dissection in clinical Stage I nonseminomatous germ cell tumor: a comparison study. *Urology. 2006*;68(1):154-60.
30. Rossen PB, Pedersen AF, Zachariae R, von der Maase H. Health-related quality of life in long-term survivors of testicular cancer. *J Clin Oncol. 2009*;27(35):5993-9.
31. Rudberg L, Carlsson M, Nilsson S, Wikblad K. Self-perceived physical, psychologic, and general symptoms in survivors of testicular cancer 3 to 13 years after treatment. *Cancer Nurs. 2002*;25(3):187-95.
32. Rudberg L, Nilsson S, Wikblad K. Health-related quality of life in survivors of testicular cancer 3 to 13 years after treatment. *Journal of Psychosocial Oncology. 2000*;18(3):19-31.
33. Schmidt AH, Hoyer M, Jensen BFS, Agerbaek M. Limited post-chemotherapy retroperitoneal resection of residual tumour in non-seminomatous testicular cancer: complications, outcome and quality of life. *Acta Oncol. 2018*;57(8):1084-93.
34. Skaali T, Foss SD, Dahl AA. A prospective study of cognitive complaints in patients with testicular cancer. *Clin Genitourin Cancer. 2011*;9(1):6-13.
35. Skaali T, Fossa SD, Andersson S, Cvancarova M, Langberg CW, Lehne G, et al. Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress. *J Psychosom Res. 2011*;70(5):403-10.
36. Skalleberg J, Smastuen MC, Oldenburg J, Osnes T, Fossa SD, Bunne M. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up. *Laryngoscope. 2020*;17:17.
37. Skoogh J, Steineck G, Stierner U, Cavallin-Stahl E, Wilderang U, Wallin A, et al. Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish population-based study 3-26 years after treatment. *Acta Oncol. 2012*;51(2):185-97.
38. Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. *J Clin Oncol. 2012*;30(3):300-7.
39. Vidrine DJ, Hoekstra-Weebers JE, Hoekstra HJ, Tuinman MA, Marani S, Gritz ER. The effects of testicular cancer treatment on health-related quality of life. *Urology. 2010*;75(3):636-41.
40. Whitford HS, Kalinowski P, Schembri A, Grimison P, Stockler M, Martin A, et al. The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer. *Supportive Care in Cancer. 2019*.
41. Wortel RC, Ghidry Alemayehu W, Incrocci L. Orchiectomy and radiotherapy for stage I-II testicular seminoma: a prospective evaluation of short-term effects on body image and sexual function. *J Sex Med. 2015*;12(1):210-8.